Cargando…
The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
BACKGROUND: Despite new drugs, metastatic prostate cancer remains fatal. Growing interest in the latest approved cabazitaxel taxane drug has markedly increased due to the survival benefits conferred when used at an earlier stage of the disease, its promising new therapeutic combination and formulati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266300/ https://www.ncbi.nlm.nih.gov/pubmed/32484838 http://dx.doi.org/10.1371/journal.pone.0234078 |
_version_ | 1783541280845856768 |
---|---|
author | Sennoune, Souad R. Nelius, Thomas Jarvis, Courtney Pruitt, Kevin Kottapalli, Kameswara Rao Filleur, Stéphanie |
author_facet | Sennoune, Souad R. Nelius, Thomas Jarvis, Courtney Pruitt, Kevin Kottapalli, Kameswara Rao Filleur, Stéphanie |
author_sort | Sennoune, Souad R. |
collection | PubMed |
description | BACKGROUND: Despite new drugs, metastatic prostate cancer remains fatal. Growing interest in the latest approved cabazitaxel taxane drug has markedly increased due to the survival benefits conferred when used at an earlier stage of the disease, its promising new therapeutic combination and formulation, and its differential toxicity. Still cabazitaxel’s mechanisms of resistance are poorly characterized. The goal of this study was thus to generate a new model of acquired resistance against cabazitaxel in order to unravel cabazitaxel’s resistance mechanisms. METHODS: Du145 cells were cultured with increasing concentrations of cabazitaxel, docetaxel/ taxane control or placebo/age-matched control. Once resistance was reached, Epithelial-to-Mesenchymal Translation (EMT) was tested by cell morphology, cell migration, and E/M markers expression profile. Cell transcriptomics were determined by RNA sequencing; related pathways were identified using IPA, PANTHER or KEGG software. The Wnt pathway was analyzed by western blotting, pharmacological and knock-down studies. RESULTS: While age-matched Du145 cells were sensitive to both taxane drugs, docetaxel-resistant cells were only resistant to docetaxel and cabazitaxel-resistant cells showed a partial cross-resistance to both drugs concomitant to EMT. Using RNA-sequencing, the Wnt non-canonical pathway was identified as exclusively activated in cabazitaxel resistant cells while the Wnt canonical pathway was restricted to docetaxel-resistant cells. Cabazitaxel-resistant cells showed a minimal crossover in the Wnt-pathway-related genes linked to docetaxel resistance validating our unique model of acquired resistance to cabazitaxel. Pharmacological and western blot studies confirmed these findings and suggest the implication of the Tyrosine kinase Ror2 receptor in cabazitaxel resistant cells. Variation in Ror2 expression level altered the sensitivity of prostate cancer cells to both drugs identifying a possible new target for taxane resistance. CONCLUSION: Our study represents the first demonstration that while Wnt pathway seems to play an important role in taxanes resistance, Wnt effectors responsible for taxane specificity remain un-identified prompting the need for more studies. |
format | Online Article Text |
id | pubmed-7266300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-72663002020-06-10 The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells Sennoune, Souad R. Nelius, Thomas Jarvis, Courtney Pruitt, Kevin Kottapalli, Kameswara Rao Filleur, Stéphanie PLoS One Research Article BACKGROUND: Despite new drugs, metastatic prostate cancer remains fatal. Growing interest in the latest approved cabazitaxel taxane drug has markedly increased due to the survival benefits conferred when used at an earlier stage of the disease, its promising new therapeutic combination and formulation, and its differential toxicity. Still cabazitaxel’s mechanisms of resistance are poorly characterized. The goal of this study was thus to generate a new model of acquired resistance against cabazitaxel in order to unravel cabazitaxel’s resistance mechanisms. METHODS: Du145 cells were cultured with increasing concentrations of cabazitaxel, docetaxel/ taxane control or placebo/age-matched control. Once resistance was reached, Epithelial-to-Mesenchymal Translation (EMT) was tested by cell morphology, cell migration, and E/M markers expression profile. Cell transcriptomics were determined by RNA sequencing; related pathways were identified using IPA, PANTHER or KEGG software. The Wnt pathway was analyzed by western blotting, pharmacological and knock-down studies. RESULTS: While age-matched Du145 cells were sensitive to both taxane drugs, docetaxel-resistant cells were only resistant to docetaxel and cabazitaxel-resistant cells showed a partial cross-resistance to both drugs concomitant to EMT. Using RNA-sequencing, the Wnt non-canonical pathway was identified as exclusively activated in cabazitaxel resistant cells while the Wnt canonical pathway was restricted to docetaxel-resistant cells. Cabazitaxel-resistant cells showed a minimal crossover in the Wnt-pathway-related genes linked to docetaxel resistance validating our unique model of acquired resistance to cabazitaxel. Pharmacological and western blot studies confirmed these findings and suggest the implication of the Tyrosine kinase Ror2 receptor in cabazitaxel resistant cells. Variation in Ror2 expression level altered the sensitivity of prostate cancer cells to both drugs identifying a possible new target for taxane resistance. CONCLUSION: Our study represents the first demonstration that while Wnt pathway seems to play an important role in taxanes resistance, Wnt effectors responsible for taxane specificity remain un-identified prompting the need for more studies. Public Library of Science 2020-06-02 /pmc/articles/PMC7266300/ /pubmed/32484838 http://dx.doi.org/10.1371/journal.pone.0234078 Text en © 2020 Sennoune et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Sennoune, Souad R. Nelius, Thomas Jarvis, Courtney Pruitt, Kevin Kottapalli, Kameswara Rao Filleur, Stéphanie The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells |
title | The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells |
title_full | The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells |
title_fullStr | The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells |
title_full_unstemmed | The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells |
title_short | The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells |
title_sort | wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266300/ https://www.ncbi.nlm.nih.gov/pubmed/32484838 http://dx.doi.org/10.1371/journal.pone.0234078 |
work_keys_str_mv | AT sennounesouadr thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT neliusthomas thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT jarviscourtney thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT pruittkevin thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT kottapallikameswararao thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT filleurstephanie thewntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT sennounesouadr wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT neliusthomas wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT jarviscourtney wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT pruittkevin wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT kottapallikameswararao wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells AT filleurstephanie wntnoncanonicalsignalingmodulatescabazitaxelsensitivityinprostatecancercells |